 Helicon is listed on the Australian Securities Exchange. The Company's business is to identify and exploit niche market opportunities in the biomedical markets of North Asia, specifically China and to participate in the significant growth that has been projected for these markets over the next 25 years.
Helicon looks for "Special Situations" for advanced Western biopharmaceutical products that are not available in China or other North Asian Markets or where there are market needs that are not being adequately provided for.
Helicon's product partners are likely to be innovative small to medium sized pharmaceutical and healthcare enterprises focused largely on western markets.
Helicon seeks exclusive licenses for the designated markets and utilises a low cost operating overhead base in combination with established channel partners for product registration, distribution, marketing, and sales.
|
|
ASX S&P200
ASX:HCG
